Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Articles
F. Hoffmann-la Roche Ltd.
Headquarters:
Basel, Switzerland
Website:
N/A
Year Founded:
1996
Status:
Out of Business
BioCentury
|
Mar 31, 2021
Regulation
March 31 Quick Takes: Basket of EU approvals includes MS, SMA drugs; plus Amarin, AbbVie, Cara-Vifor
The European Commission approved Kesimpta ofatumumab from Novartis AG (NYSE:NVS; SIX:NOVN) to treat relapsing forms of multiple sclerosis. The subcutaneously administered drug was originally
Read More
BioCentury
|
Oct 19, 2018
Company News
Revolution acquiring Warp Drive
Read More
BioCentury
|
May 16, 2017
Distillery Therapeutics
Neurology
Read More
BioCentury
|
Apr 15, 2013
Company News
Human Genome Sciences, Roche deal
Read More
BioCentury
|
Apr 15, 2013
Clinical News
Insulin-like growth factor-1 data
Read More
BioCentury
|
Apr 15, 2013
Company News
New England Biolabs, Roche enabling technology news
Read More
BioCentury
|
Mar 4, 2013
Clinical News
Roche preclinical data
Read More
BioCentury
|
Feb 25, 2013
Company News
Roche, University of Pittsburgh, University of Texas Southwestern Medical Center neurology, genomics news
Read More
BioCentury
|
Feb 18, 2013
Company News
Chiasma, Novartis, Roche deal
Read More
BioCentury
|
Feb 18, 2013
Company News
Genentech, RQx Pharmaceuticals, Roche deal
Read More
Items per page:
10
1 - 10 of 336